SIGA Technologies, Inc.

NASDAQ•SIGA

CEO: Dr. Dennis E. Hruby Ph.D.

板块: Healthcare

行业: Drug Manufacturers - Specialty & Generic

上市日期: 1997-09-10

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

联系方式

31 East 62nd Street, New York, NY, 10065, United States

212-672-9100

www.siga.com

市值

$319.53M

市盈率 (TTM)

13.7

14.6

股息率

26.9%

52周最高

$9.62

52周最低

$4.30

52周范围

排名30Top 19.5%

5.1

F-Score

改良版 Piotroski 分析

基于 10 年期基本面

一般 • 5.1 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2016-2025

财务仪表盘

Q4 2025 数据

营业收入

$3.80M+0.00%

近4季度走势

每股收益

-$0.08+0.00%

近4季度走势

自由现金流

-$11.30M+0.00%

近4季度走势

2025 Annual 财报亮点

核心亮点

Net Income Decreased Sharply Net income for 2025 was $23.28M, a substantial decrease from $59.21M reported in the prior year period.

Total Revenues Fell Significantly Total revenues for 2025 totaled $94.57M, reflecting a significant contraction from $138.72M recorded in 2024.

Cash Position Remains Robust Cash and cash equivalents held steady at $155.0M at December 31, 2025, supporting liquidity needs for the near term.

BARDA Contract Execution Cumulative oral TPOXX® delivery value under the 19C BARDA Contract reached $450.2M as of December 31, 2025.

关注风险

Dependence on Government Contracts Substantial future revenue relies on U.S. Government commitment; failure to secure new contracts materially harms operations.

International Sales Dropped International sales sharply declined to $5.82M in 2025 from $23.0M in 2024, limiting diversification efforts.

EMA Mpox Authorization Review EMA CHMP referral on mpox effectiveness may recommend withdrawal, negatively impacting anticipated revenue streams.

Fixed Price Contract Exposure Fixed-price government contracts require absorbing cost overruns, potentially reducing profitability or causing material losses.

前瞻展望

Smallpox PEP Submission Targeted Targeting Supplemental NDA submission for oral TPOXX® smallpox PEP indication within the next twelve months based on trial results.

IV TPOXX Manufacturing Transition Actively transferring IV TPOXX® manufacturing process from Patheon to a new third-party site, requiring FDA approval.

Expanding International Sales Efforts Reacquired international promotional rights; building out internal sales organization to pursue recurring non-U.S. government sales.

同行对比

营业收入 (TTM)

OFIX

$822.31M

+2.9%

EBS

$742.90M

-28.8%

SNDL

$677.36M

+2.8%

毛利率 (最新季度)

RIGL

91.5%

+7.7pp

KALV

90.4%

+0.0pp

ESPR

83.5%

-30.0pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
OLMA	$1.39B	-9.0	-42.9%	0.2%
VTYX	$1.00B	-9.4	-48.1%	4.7%
KALV	$1.00B	-5.9	-444.4%	84.7%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

-18.6%

增长承压

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

50%

现金流需要关注

深度研究

下次财报:2026年4月30日

每股收益:-

营业收入:-

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据